Dual Delivery of Gemcitabine and Paclitaxel by Wet‐Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation

2020 ◽  
Vol 9 (21) ◽  
pp. 2001115
Author(s):  
Samantha J. Wade ◽  
Zeliha Sahin ◽  
Ann‐Katrin Piper ◽  
Sepehr Talebian ◽  
Morteza Aghmesheh ◽  
...  
2019 ◽  
Vol 18 ◽  
pp. 153303381882431 ◽  
Author(s):  
Yan Chen ◽  
Huiyun Zhu ◽  
Yuqiong Wang ◽  
Yingxiao Song ◽  
Pingping Zhang ◽  
...  

The role of microRNA-132 in human pancreatic ductal adenocarcinomas is still ambiguous. We explored the association between microRNA-132 and pancreatic ductal adenocarcinoma prognosis. The expression of microRNA-132 in 50 pancreatic ductal adenocarcinoma tissue samples and pancreatic ductal adenocarcinoma cell lines was examined, and the association between its expression and pancreatic ductal adenocarcinoma prognosis was assessed. Functional analysis and factors downstream of microRNA-132 were investigated. Kaplan-Meier survival curves showed that high expression of microRNA-132 was a significant prognostic factor for 1-year survival of patients with pancreatic ductal adenocarcinoma ( P = .028). Multivariate analysis for overall survival indicated that high expression of microRNA-132 was an independent prognostic factor for patients with pancreatic ductal adenocarcinoma ( P = .044). Low expression of microRNA-132 was associated with poor prognosis in pancreatic ductal adenocarcinoma. Ectopic expression of microRNA-132 significantly inhibited proliferation and promoted apoptosis of 2 pancreatic ductal adenocarcinoma cell lines. Bioinformatic analysis revealed that microRNA-132 may exert its effects on pancreatic ductal adenocarcinoma through downregulating mitogen-activated protein kinase 3 and nuclear transcription factor Y subunit α. The results of this study further our understanding of the relationship between microRNA-132 and pancreatic ductal adenocarcinoma by showing that microRNA-132 might inhibit the progression of pancreatic ductal adenocarcinoma by regulating mitogen-activated protein kinase and nuclear transcription factor Y subunit alpha.


Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1869 ◽  
Author(s):  
Can Huang ◽  
Wenjun Lan ◽  
Nicolas Fraunhoffer ◽  
Analía Meilerman ◽  
Juan Iovanna ◽  
...  

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with almost no curative chemotherapeutic treatment. Besides the development of new compounds, repurposing of approved drugs to treat cancer, alone or in combination, has become an attractive strategy, showing many therapeutic and economic advantages. However, it is necessary to improve our knowledge about the mechanism of cell death elicited by approved drugs itself, but also to rationally develop more powerful multidrug treatments. In this work, we focus our attention on determining the mechanism promoting cell death following trifluoperazine (TFP) treatment, which is an antipsychotic drug with strong anticancer activity in PDAC. We demonstrate that TFP induces cell death by apoptosis and necroptosis, which can be partially inhibited by Z-VAD-FMK as well as necrostatin-1, respectively. This cell death promotion is triggered by a poor ATP content, observed in TFP-treated cells as a consequence of a dramatic decrease in OXPHOS metabolism due to mitochondrial stress. Remarkably, mitochondrial homeostasis was seriously affected, and a loss of mitochondrial membrane potential and ROS overproduction was observed. Moreover, this mitochondrial stress was coupled with an ER stress and the activation of the endoplasmic-reticulum-associated protein degradation (ERAD) and the unf olded protein response (UPR) pathways. We took advantage of this information and inhibited this process by using the proteasome inhibitors MG-132 or bortezomib compounds in combination with TFP and found a significant improvement of the anticancer effect of the TFP on primary PDAC-derived cells. In conclusion, this study not only uncovers the molecular mechanisms that are triggered upon TFP-treatment but also its possible combination with bortezomib for the future development of therapies for pancreatic cancer.


2014 ◽  
Vol 46 (3) ◽  
pp. 1099-1108 ◽  
Author(s):  
ELISA DALLA POZZA ◽  
ILARIA DANDO ◽  
GIULIA BIONDANI ◽  
JESSICA BRANDI ◽  
CHIARA COSTANZO ◽  
...  

2017 ◽  
Vol 14 (1) ◽  
pp. 903-908 ◽  
Author(s):  
Shuya Kasai ◽  
Takuya Sasaki ◽  
Ayano Watanabe ◽  
Masao Nishiya ◽  
Shinji Yasuhira ◽  
...  

2014 ◽  
Vol 88 (16) ◽  
pp. 9321-9334 ◽  
Author(s):  
S. B. Kasloff ◽  
M. S. Pizzuto ◽  
M. Silic-Benussi ◽  
S. Pavone ◽  
V. Ciminale ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document